Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma.
Gulati S, Barata PC, Elliott A, Bilen MA, Burgess EF, Choueiri TK, Darabi S, Dawson NA, Gartrell BA, Hammers HJ, Heath EI, Magee D, Rao A, Ryan CJ, Twardowski P, Wei S, Brugarolas J, Zhang T, Zibelman MR, Nabhan C, McKay RR. Gulati S, et al. Among authors: hammers hj. J Clin Invest. 2024 May 30;134(14):e176230. doi: 10.1172/JCI176230. J Clin Invest. 2024. PMID: 39007269 Free PMC article.
Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram.
Keizman D, Gottfried M, Ish-Shalom M, Maimon N, Peer A, Neumann A, Rosenbaum E, Kovel S, Pili R, Sinibaldi V, Carducci MA, Hammers H, Eisenberger MA, Sella A. Keizman D, et al. Oncologist. 2012;17(12):1508-14. doi: 10.1634/theoncologist.2012-0125. Epub 2012 Sep 12. Oncologist. 2012. PMID: 22971522 Free PMC article.
Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity.
Hembrough TA, Ruiz JF, Swerdlow BM, Swartz GM, Hammers HJ, Zhang L, Plum SM, Williams MS, Strickland DK, Pribluda VS. Hembrough TA, et al. Among authors: hammers hj. Blood. 2004 May 1;103(9):3374-80. doi: 10.1182/blood-2003-07-2234. Epub 2004 Jan 22. Blood. 2004. PMID: 14739228 Free article.
Withaferin A is a potent inhibitor of angiogenesis.
Mohan R, Hammers HJ, Bargagna-Mohan P, Zhan XH, Herbstritt CJ, Ruiz A, Zhang L, Hanson AD, Conner BP, Rougas J, Pribluda VS. Mohan R, et al. Among authors: hammers hj. Angiogenesis. 2004;7(2):115-22. doi: 10.1007/s10456-004-1026-3. Angiogenesis. 2004. PMID: 15516832
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade.
Naidoo J, Cappelli LC, Forde PM, Marrone KA, Lipson EJ, Hammers HJ, Sharfman WH, Le DT, Baer AN, Shah AA, Albayda J, Manno RL, Haque U, Gutierrez AK, Bingham CO 3rd, Brahmer JR. Naidoo J, et al. Among authors: hammers hj. Oncologist. 2017 Jun;22(6):627-630. doi: 10.1634/theoncologist.2016-0390. Epub 2017 Jun 2. Oncologist. 2017. PMID: 28576858 Free PMC article.
Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen.
Hussain M, Corn PG, Michaelson MD, Hammers HJ, Alumkal JJ, Ryan CJ, Bruce JY, Moran S, Lee SY, Lin HM, George DJ; Prostate Cancer Clinical Trials Consortium, a program of the Department of Defense Prostate Cancer Research Program and the Prostate Cancer Foundation. Hussain M, et al. Among authors: hammers hj. Clin Cancer Res. 2014 Aug 15;20(16):4218-27. doi: 10.1158/1078-0432.CCR-14-0356. Epub 2014 Jun 25. Clin Cancer Res. 2014. PMID: 24965748 Clinical Trial.
129 results